CN117999258A - Gpr52调节剂化合物 - Google Patents

Gpr52调节剂化合物 Download PDF

Info

Publication number
CN117999258A
CN117999258A CN202280062419.2A CN202280062419A CN117999258A CN 117999258 A CN117999258 A CN 117999258A CN 202280062419 A CN202280062419 A CN 202280062419A CN 117999258 A CN117999258 A CN 117999258A
Authority
CN
China
Prior art keywords
disorder
disorders
optionally substituted
acid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280062419.2A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂芬·保罗·沃特森
奈杰尔·艾伦·斯温
迈克尔·阿里斯代尔·奥布莱恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of CN117999258A publication Critical patent/CN117999258A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280062419.2A 2021-09-15 2022-09-15 Gpr52调节剂化合物 Pending CN117999258A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2113186.7 2021-09-15
GBGB2113186.7A GB202113186D0 (en) 2021-09-15 2021-09-15 GPR52 Modulator compounds
PCT/GB2022/052328 WO2023041909A1 (en) 2021-09-15 2022-09-15 Gpr52 modulator compounds

Publications (1)

Publication Number Publication Date
CN117999258A true CN117999258A (zh) 2024-05-07

Family

ID=78149263

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280062419.2A Pending CN117999258A (zh) 2021-09-15 2022-09-15 Gpr52调节剂化合物

Country Status (22)

Country Link
US (1) US20240376070A1 (cg-RX-API-DMAC10.html)
EP (1) EP4401833B1 (cg-RX-API-DMAC10.html)
JP (1) JP2024535860A (cg-RX-API-DMAC10.html)
KR (1) KR20240058852A (cg-RX-API-DMAC10.html)
CN (1) CN117999258A (cg-RX-API-DMAC10.html)
AU (1) AU2022348201A1 (cg-RX-API-DMAC10.html)
CA (1) CA3232606A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024000742A1 (cg-RX-API-DMAC10.html)
DK (1) DK4401833T3 (cg-RX-API-DMAC10.html)
ES (1) ES3053759T3 (cg-RX-API-DMAC10.html)
FI (1) FI4401833T3 (cg-RX-API-DMAC10.html)
GB (1) GB202113186D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20251420T1 (cg-RX-API-DMAC10.html)
IL (1) IL311015A (cg-RX-API-DMAC10.html)
LT (1) LT4401833T (cg-RX-API-DMAC10.html)
MX (1) MX2024003248A (cg-RX-API-DMAC10.html)
PL (1) PL4401833T3 (cg-RX-API-DMAC10.html)
PT (1) PT4401833T (cg-RX-API-DMAC10.html)
RS (1) RS67399B1 (cg-RX-API-DMAC10.html)
SI (1) SI4401833T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202500449T1 (cg-RX-API-DMAC10.html)
WO (1) WO2023041909A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025252061A1 (zh) * 2024-06-04 2025-12-11 海思科医药集团股份有限公司 一种gpr52激动剂及其在医药上的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4139284A1 (en) 2020-04-22 2023-03-01 Neurocrine Biosciences, Inc. Gpr52 modulators and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009107391A1 (ja) * 2008-02-27 2011-06-30 武田薬品工業株式会社 6員芳香環含有化合物
MX373876B (es) 2015-04-29 2020-03-26 Arena Pharm Inc 1-heteroaril-indolin-4-carboxamidas como moduladores de gpr52 útiles para el tratamiento o prevención de trastornos relacionados a las mismas.
CN111094278B (zh) * 2017-09-13 2023-07-14 诺华股份有限公司 二苯基衍生物及其用途
CN114650992A (zh) * 2019-11-08 2022-06-21 赫普泰雅治疗有限公司 Gpr52调节剂化合物
GB202003668D0 (en) 2020-03-13 2020-04-29 Heptares Therapeutics Ltd GPR52 Modulator compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025252061A1 (zh) * 2024-06-04 2025-12-11 海思科医药集团股份有限公司 一种gpr52激动剂及其在医药上的应用

Also Published As

Publication number Publication date
WO2023041909A1 (en) 2023-03-23
IL311015A (en) 2024-04-01
SMT202500449T1 (it) 2026-01-12
CL2024000742A1 (es) 2024-09-27
US20240376070A1 (en) 2024-11-14
JP2024535860A (ja) 2024-10-02
PL4401833T3 (pl) 2026-02-16
LT4401833T (lt) 2025-12-10
MX2024003248A (es) 2024-04-02
DK4401833T3 (da) 2025-11-17
RS67399B1 (sr) 2025-11-28
ES3053759T3 (en) 2026-01-26
KR20240058852A (ko) 2024-05-07
HRP20251420T1 (hr) 2026-01-02
AU2022348201A1 (en) 2024-03-28
EP4401833B1 (en) 2025-10-22
EP4401833A1 (en) 2024-07-24
GB202113186D0 (en) 2021-10-27
PT4401833T (pt) 2025-11-14
SI4401833T1 (sl) 2026-01-30
CA3232606A1 (en) 2023-03-23
FI4401833T3 (fi) 2025-11-25

Similar Documents

Publication Publication Date Title
CN115515681B (zh) Gpr52调节剂化合物
EP3209656B1 (en) Indole carboxamides compounds useful as kinase inhibitors
CN115210233B (zh) 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物以及包含其的药物组合物
CZ361392A3 (en) Novel azaheterocyclylmethyl-chromans
CN116507622B (zh) Gpr52调节剂化合物
KR20130046436A (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n''-다이아릴티오우레아 및 n,n''-다이아릴우레아, 이의 제조방법 및 이의 용도
EP4401833B1 (en) Gpr52 modulator compounds
CZ325196A3 (en) Derivatives of hydroximic acid, pharmaceutical compositions containing thereof, process of their preparation and intermediates used in the preparation process
CN121335897A (zh) 作为cd38抑制剂用于治疗cns病症的1,3-噻唑和1,2,4-噻二唑
CZ327494A3 (en) Esters of nicotinic acid and process for preparing thereof
HK40107480A (en) Gpr52 modulator compounds
HK40107480B (en) Gpr52 modulator compounds
DE69707080T2 (de) Pyrrolidinonderivate und ihre Verwendung als antipsychotische Arzneimittel
CA3116506A1 (en) Pyrrolo-pyridazine derivatives as muscarinic m1 receptor positive allosteric modulators
RU2844473C1 (ru) Соединения модуляторы gpr52
CN119874676A (zh) 一种pi3k抑制剂及其制备方法和用途
HK40085749A (en) P2x3 modulators
CN1984910A (zh) 适用于神经变性疾病治疗的哌啶、哌嗪或者吗啉或它们的7元类似物的二聚化合物
HK40075698B (en) 1,3,4 oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information

Country or region after: Britain

Address after: Cambridge, County of Cambridge, UK

Applicant after: Nexla Pharmaceuticals UK Ltd.

Address before: Cambridge, County of Cambridge, UK

Applicant before: Heptares Therapeutics Ltd.

Country or region before: Britain

CB02 Change of applicant information
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination